The annual general meeting of shareholders of 8 May 2007 approved the appropriation of the accumulated loss in the Statutory accounts. The accumulated Statutory loss of CHF 31.1 million was compensated with an equal amount of share premium in the general reserves. This concerns a movement within equity and has no impact on the total amount.
Based on current expectations and including pre-launch activities, NDA preparation and the recently announced development plans, cash used in operating activities in the second half of the year is forecast to remain around the level of the first half.
During the first half of 2007, the total number of common shares outstanding rose by 12.1% to 19.3 million. The increase was due to the placing of March, involving 1.7 million new shares from the authorised capital. In addition, 0.4 million shares were issued from conditional capital due to the exercise of staff options. Early August 2007, the number of outstanding shares increased by an additional 0.3% in connection with the payment related to the closing of the TLT transaction.
As per 28 August 2007, Arpida has four shareholders with stakes above 5%: Fidelity (10.7%), Deutsche Bank (10.1%), Schroders (7.8%) and Capital Group (5.0%). In accordance with SWX Swiss Exchange these stakes are considered free-float, which consequently is 100%.
Intravenous iclaprim in cSSSI Phase III programme completed
In February 2007, Arpida reported positive results of a Phase I trial
with intravenous iclaprim in volunteers with varying degrees of renal and
hepatic impairment and obesity. The predictable pharmacokinetics observed
in these populations would su
Copyright©2007 PR Newswire.
All rights reserved